Status:
COMPLETED
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
Lead Sponsor:
Cytos Biotechnology AG
Conditions:
Allergic Bronchial Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.
Eligibility Criteria
Inclusion
- Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids
- Further criteria as defined in the study protocol
Exclusion
- Use of oral corticosteroids within past 3 months
- Hospitalization for asthma exacerbation within past 6 months
- Uncontrolled asthma
- Contraindication to any study test or procedure
- Further criteria as defined in the study protocol
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00890734
Start Date
April 1 2009
End Date
November 1 2010
Last Update
February 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cytos Investigator Sites
Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany